| Trial Identifier: | D081KC00001 |
| Sponsor: | AstraZeneca |
| Collaborator: |
IQVIA (formerly QuintilesIMS)
|
| Start Date: | March 2016 |
| Primary Completion Date: | September 2021 |
| Study Completion Date: | September 2026 |
| Condition: | Breast Cancer; Gastric Cancer; Ovarian Cancer; Lung Cancer |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Country | Location |
|---|---|
| CH | Chur, CH, CH-7000 |
| CH | Lausanne, CH, 1011 |
| FR | Bordeaux, FR, 33076 |
| FR | Caen Cedex 05, FR, 14076 |
| FR | Clermont Ferrand cedex 01, FR, 63011 |
| FR | Dijon cedex, FR, 21079 |
| FR | Marseille CEDEX 5, FR, 13385 |
| FR | Nantes, FR, 44202 |
| FR | Paris cedex 14, FR, 75014 |
| FR | Pierre Benit CEDEX, FR, 69495 |
| FR | Toulouse Cedex 9, FR, 31059 |
| FR | Villejuif Cedex, FR, 94805 |
| GB | Cambridge, GB, CB2 0QQ |
| GB | Dundee, GB, DD1 9SY |
| GB | Glasgow, GB, G12 0YN |
| GB | Greater London, GB, SW3 6JJ |
| GB | London, GB, SE1 9RY |
| GB | London, GB, NW1 2PG |
| GB | Manchester, GB, M20 4BX |
| GB | Newcastle Upon Tyne, GB, NE7 7DN |
| GB | Sutton, GB, SM2 5PT |
| IL | Haifa, IL, 91096 |
| IL | Jerusalem, IL, 91031 |
| IL | Petah Tikva, IL, 49100 |
| IL | Ramat Gan, IL, 5265601 |
| IL | Tel Aviv, IL, 6423906 |
| KR | Goyang-si, KR, 10408 |
| KR | Seongnam-si, KR, 13620 |
| KR | Seoul, KR, 06273 |
| KR | Seoul, KR, 135-710 |
| KR | Seoul, KR, 06591 |
| KR | Seoul, KR, 03722 |
| KR | Seoul, KR, 03080 |
| KR | Seoul, KR, 05505 |
| NL | Amsterdam, NL, 1066 CX |
| NL | Amsterdam, NL, 1081 HV |
| NL | Maastricht, NL, 6229 HX |
| NL | Nijmegen, NL, 6525 GA |
| NL | Rotterdam, NL, 3075 EA |
| NL | UTRECHT, NL, 3584 CX |
| US, GA | Newnan, GA, US, 30265 |
| US, MA | Boston, MA, US, 02114 |
| US, MD | Towson, MD, US, 21204 |
| US, MI | Detroit, MI, US, 48202 |
| US, MO | Saint Louis, MO, US, 63110 |
| US, OH | Hilliard, OH, US, 43026 |
| US, PA | Philadelphia, PA, US, 19104 |